-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"
Pharmaceutical Network Industry Dynamic" Recently, the Inner Mongolia Medical Insurance Bureau issued a notice that from March 1, 2020 to June 30, 2020, due to the rise of raw materials, production line transformation, drug approval was withdrawn and other reasons, resulting in Texas German medicine, Qilu Pharmaceuticals, Shandong Lu anti- , Sunflower Pharmaceuticals, Shenwei Pharmaceuticals and other 20 pharmaceutical manufacturers actively applied for drug withdrawal, 40 heavy-duty drugs to stop productiona large number of pharmaceutical companies to actively apply for withdrawal, 40 heavy-duty drugs to stop production
in addition, the above 20 pharmaceutical companies also to the Inner Mongolia Medical Insurance Bureau promised to apply for withdrawal of the results of drugs published in Inner Mongolia after the results of the withdrawal, if there is supply in other provinces and cities, accept the list of bad records, and in accordance with the "Inner Mongolia Autonomous Region drug centralized procurement of bad records management measuresThis means that these products will be gradually withdrawn from the public hospital marketin fact, pharmaceutical enterprises take the initiative to apply for product cancellation network, is a common phenomenon in the pharmaceutical industry in recent yearsData show that as of May this year, only enterprises have actively applied for the withdrawal of drugs has reached nearly a thousandOn April 23, Hainan Province Public Resources Trading Service Center issued the "notice on the public ity of new hanging network and withdrawal of drug information", it mentions aweic acid tablets, quipibon tablets, lithium carbonate tablets, heparin sodium injection, hydrochloric acid bubicain injection 5 drugs due to rising costs, apply for the withdrawal of the netMay 25, Shanxi Province pharmaceutical centralized bidding procurement network issued two notices, including Chenxin Pharmaceuticals, Chengdu Diao Pharmaceutical Group, Shi Pharmaceutical Group, Ha Pharmaceutical Group, Shenwei Pharmaceuticals and other 25 enterprises to apply for the cancellation of the direct network product platform hanging network qualifications, involving 66 pharmaceutical product regulations, enterprises also make a national unified non-supply commitmentThe drugs removed include sodium chloride injections, double yellow particles, etcin addition to the above-mentioned provinces, Sichuan, Fujian, Zhejiang, Gansu and other provinces have also appeared this year pharmaceutical companies actively scrap the standard or withdraw the hanging networkSo why do companies have to quit the market at the risk of being included in a bad record? Insiders say that the withdrawal of enterprises from the market is also a last resortOn the one hand, the raw materials and production costs of pharmaceuticalproducts are increasing year by year, on the other hand, the price of many drugs has been reduced and then reduced by policies such as the purchase of the amount of the beltDouble factors lead to small profits of pharmaceutical companies or even not to make money at all, so many pharmaceutical companies have to bear the pain of abandoning the bid, withdrawing the network, or even stop productionit is worth noting that after many varieties exited the public hospital market, it can only turn to the retail market, but in recent years, retail pharmacies and other drug prices are also in line with the collection price, unlimited is depressedThis means that in the future only through rebates to do the market products will have no way to go, pharmaceutical representatives and agents can only actively accelerate the transformationIn addition, in the future, drug sales channels can not control their own enterprises, the cost can not meet the national bidding price requirements of enterprises, is also destined to be eliminatedin general, in the context of pharmaceutical reform, pharmaceutical companies face a very large test, not only need to bear the trend of drug prices, but also need to strictly control the quality of drugsTherefore, some enterprises risk default, breach of trust, the risk of abandonment of the bid, it is helplessAnd for the rest of the enterprise, in the face of low-cost drug waste, either to give a reasonable profit, or can only take more measures to reduce costs.